2025 PACUPrep BCCCP Preparatory Course Initial Resuscitation and Fluid Management in Trauma Evidence-Based Fluid Selection and Transfusion Strategies in Trauma Resuscitation
Fluid and Transfusion Strategies in Trauma

Evidence-Based Fluid Selection and Transfusion Strategies in Trauma Resuscitation

Objectives Icon A clipboard with a checkmark, symbolizing learning goals.

Learning Objective

Design an evidence-based fluid resuscitation strategy for initial trauma management, balancing restoration of volume, correction of coagulopathy, and preservation of end-organ perfusion.

1. Crystalloids in Trauma Resuscitation

Crystalloid solutions are the cornerstone of initial fluid resuscitation in trauma. Modern practice favors balanced solutions over normal saline to mitigate the risks of metabolic acidosis and acute kidney injury associated with large-volume resuscitation.

A. Composition and Comparison

  • Normal Saline (0.9% NaCl): Contains 154 mEq/L of both sodium and chloride, resulting in a strong ion difference (SID) of zero. Its high chloride load is a primary driver of non-anion gap hyperchloremic metabolic acidosis.
  • Lactated Ringer’s (LR): A balanced solution containing 130 mEq/L sodium, 109 mEq/L chloride, and 28 mmol/L of lactate, which is metabolized by the liver to bicarbonate, helping to buffer acidosis.
  • Plasma-Lyte: Another balanced solution with 140 mEq/L sodium and 98 mEq/L chloride. It uses acetate and gluconate as buffers, which are metabolized by muscle and other tissues, making it a potential alternative in patients with severe hepatic dysfunction.

B. Risks of Large-Volume Crystalloid Resuscitation

While necessary, excessive crystalloid administration (>3–5 L) is associated with significant harm. Due to their low oncotic pressure, only about 20-25% of the infused volume remains in the intravascular space. The remainder extravasates into the interstitium, leading to:

  • Dilutional Coagulopathy: Dilution of clotting factors and platelets, worsening hemorrhage.
  • Tissue Edema: Can lead to pulmonary edema, prolonged mechanical ventilation, and abdominal compartment syndrome.
  • Metabolic Derangements: Hyperchloremic metabolic acidosis from normal saline can impair renal perfusion and immune function.
Clinical Pearl Icon A lightbulb icon, representing a clinical insight or pearl. Clinical Pearl: Transition Early

The goal of initial crystalloid therapy is to restore perfusion, not normalize blood pressure. Use balanced crystalloids for resuscitation beyond the initial 1-2 liters. In patients with evidence of hemorrhagic shock, limit total crystalloid volume and transition rapidly to a balanced blood product transfusion strategy to prevent the “triad of death”: coagulopathy, acidosis, and hypothermia.

2. Colloids and Synthetic Plasma Expanders

Colloids contain large molecules that remain in the intravascular space longer than crystalloids, providing more efficient volume expansion. However, their use in trauma is limited by cost, safety concerns, and a lack of clear benefit over crystalloids.

A. Human Albumin

Albumin is the primary protein responsible for plasma oncotic pressure. While it is an effective volume expander, its routine use in trauma is not recommended. The SAFE trial demonstrated equivalent survival compared to saline in a general ICU population but found a significant increase in mortality among patients with traumatic brain injury (TBI). Its use is generally reserved for specific indications, such as preventing renal dysfunction after large-volume paracentesis in patients with cirrhosis.

B. Synthetic Colloids

  • Hydroxyethyl Starches (HES): These agents have been definitively linked to an increased risk of acute kidney injury (AKI) and mortality in critically ill patients. Their use in trauma is strongly discouraged by all major guidelines.
  • Gelatins: These have a shorter intravascular half-life and carry a risk of coagulopathy and anaphylactic reactions. Data in trauma are limited, and they are not routinely used.
Clinical Pearl Icon A lightbulb icon, representing a clinical insight or pearl. Clinical Pearl: Avoid Synthetic Colloids

The evidence is clear: avoid all synthetic colloids (e.g., HES, gelatins) in trauma resuscitation due to the risk of significant harm, particularly AKI. Reserve albumin for very specific, non-trauma indications like post-paracentesis volume expansion in cirrhosis. For trauma, balanced crystalloids and blood products are the standard of care.

3. Blood Product Transfusion Strategies

In hemorrhagic shock, resuscitation must shift from simple volume replacement to hemostatic resuscitation. This involves the early, balanced administration of red blood cells, plasma, and platelets to restore both oxygen-carrying capacity and coagulation function.

A. Massive Transfusion Protocols (MTP)

MTPs are standardized institutional procedures designed to streamline the delivery of blood products in a balanced ratio, typically 1 unit of plasma to 1 unit of platelets to 1 unit of packed red blood cells (1:1:1). The landmark PROPPR trial showed that a 1:1:1 ratio resulted in significantly decreased mortality from exsanguination within the first 24 hours compared to a 1:1:2 ratio.

Massive Transfusion Protocol (MTP) Activation Flowchart A flowchart showing the Assessment of Blood Consumption (ABC) score criteria. A score of 2 or more triggers MTP activation, leading to a 1:1:1 transfusion of PRBCs, FFP, and platelets. MTP Activation: The ABC Score Penetrating Mechanism SBP ≤90 mmHg HR ≥120 bpm Positive FAST Score ≥ 2 Points Activate MTP (1:1:1 Ratio)
Figure 1: MTP Activation via the ABC Score. The Assessment of Blood Consumption (ABC) score is a simple, rapid tool used to predict the need for massive transfusion. A patient receives one point for each of the four criteria present on arrival. A score of 2 or greater is a common trigger for MTP activation.

B. Component Specifics

  • Packed Red Blood Cells (PRBCs): Restore oxygen-carrying capacity. Transfuse to maintain Hb >7 g/dL in most patients, or >9 g/dL in active hemorrhage or TBI.
  • Fresh Frozen Plasma (FFP): Replaces clotting factors. A typical dose is 15 mL/kg.
  • Platelets: Essential for primary hemostasis. Transfuse to maintain a platelet count >50,000/μL in active bleeding.
  • Whole Blood: Low-titer type O whole blood is increasingly used as it provides all components in a physiologic ratio. Logistical challenges currently limit its widespread availability.
Key Point Icon A key icon, representing a critical takeaway point. Key Point: Don’t Forget Calcium

Blood products are preserved with citrate, an anticoagulant that chelates calcium. During massive transfusion, this can lead to severe iatrogenic hypocalcemia, which impairs cardiac contractility and the coagulation cascade. Prophylactically supplement with calcium (e.g., 1 gram of calcium chloride or 3 grams of calcium gluconate) for every 4 units of blood products transfused.

4. Adjunct Hemostatic Therapies

Pharmacologic agents can complement blood product transfusion by targeting specific pathways in the coagulation cascade, particularly fibrinolysis and fibrinogen depletion.

A. Tranexamic Acid (TXA)

TXA is an antifibrinolytic agent that stabilizes existing clots by inhibiting the conversion of plasminogen to plasmin. The CRASH-2 trial demonstrated a significant reduction in all-cause mortality when TXA was administered within 3 hours of injury. The standard dose is a 1-gram IV bolus over 10 minutes, followed by a 1-gram infusion over 8 hours.

B. Fibrinogen Replacement

Fibrinogen is a critical substrate for clot formation and is often the first coagulation factor to reach critically low levels during hemorrhage. It can be replaced using:

  • Cryoprecipitate: A plasma-derived product containing a concentrated mix of fibrinogen, Factor VIII, Factor XIII, and von Willebrand factor. A standard adult dose is 10 units.
  • Fibrinogen Concentrate: A purified, lyophilized product that provides a more standardized dose of fibrinogen.

C. Prothrombin Complex Concentrate (PCC)

Four-factor PCC contains factors II, VII, IX, and X and is used for rapid reversal of warfarin. Its role in trauma is controversial and generally reserved for patients with pre-existing coagulopathy or as a rescue therapy when FFP is unavailable or insufficient. It carries a significant risk of thromboembolic events.

5. Endpoints and Monitoring of Resuscitation

Resuscitation is not a one-time event but a continuous process. The goal is to restore adequate end-organ perfusion without causing the harms of over-resuscitation. This requires a multi-faceted monitoring approach.

A. Clinical and Laboratory Endpoints

  • Clinical Signs: Improving mental status, capillary refill time ≤2 seconds, and warm extremities.
  • Urine Output: A target of ≥0.5 mL/kg/h is a classic indicator of adequate renal perfusion.
  • Hemodynamics: A target MAP ≥65 mmHg (or SBP ≥90 mmHg) is generally appropriate. In TBI, a higher SBP target (≥100–110 mmHg) is required to maintain cerebral perfusion pressure.
  • Lactate Clearance: A decrease in serum lactate of >10% per hour is a robust marker of improving tissue perfusion and is associated with improved survival.

B. Dynamic and Advanced Monitoring

  • Fluid Responsiveness: Dynamic parameters like stroke volume variation (SVV) or pulse pressure variation (PPV) can predict which patients will increase their cardiac output in response to a fluid bolus, helping to avoid unnecessary fluid administration.
  • Viscoelastic Testing: Assays like Thromboelastography (TEG) and Rotational Thromboelastometry (ROTEM) provide a real-time, global assessment of the entire coagulation process. They can guide goal-directed therapy by identifying specific deficits (e.g., delayed clot initiation, poor clot strength, or hyperfibrinolysis) that can be targeted with FFP, platelets, cryoprecipitate, or TXA, respectively.
Pharmacotherapy Summary: Dosing and Monitoring
Agent/Product Typical Dose Key Monitoring Clinical Notes & Contraindications
Balanced Crystalloid 250–500 mL boluses Urine output, lactate, electrolytes, fluid balance Use cautiously in heart/renal failure. Limit total volume.
Albumin 5% 5–10 mL/kg Oncotic pressure, volume status Contraindicated in TBI. No routine use in trauma.
PRBCs 1 unit (~300 mL) Hemoglobin, signs of bleeding Target Hb >7 g/dL (or >9 in active bleeding/TBI).
FFP 15 mL/kg INR, PTT, Fibrinogen Use in 1:1:1 ratio during MTP.
Platelets 1 apheresis unit Platelet count Target >50,000/μL in active bleeding.
Tranexamic Acid (TXA) 1g bolus, then 1g/8h Signs of thrombosis, renal function Give within 3 hours of injury. Avoid in isolated TBI.
Cryoprecipitate 10 units Fibrinogen level, TEG/ROTEM MA Target fibrinogen >150-200 mg/dL.
4F-PCC 25–50 IU/kg (INR-based) INR, signs of thrombosis High thrombotic risk. Reserve for warfarin reversal.

6. Special Population Considerations

Standard resuscitation protocols must be adapted to the unique physiology of specific patient populations to optimize outcomes and prevent harm.

A. Traumatic Brain Injury (TBI)

Hypotension (a single SBP <90 mmHg) is devastating in TBI and must be aggressively avoided. The primary goal is to maintain a higher blood pressure target (SBP ≥100–110 mmHg) to ensure adequate cerebral perfusion pressure. Balanced crystalloids are the fluids of choice; albumin is contraindicated due to increased mortality.

B. Elderly and Cardiorenal Disease

These patients have limited physiologic reserve and are highly susceptible to fluid overload. Employ smaller, more frequent fluid boluses (e.g., 250 mL) and use point-of-care ultrasound (e.g., cardiac and lung views) to assess volume status and cardiac function before and after each bolus. Early use of vasopressors may be necessary to support blood pressure while limiting fluid administration.

C. Pediatrics and Pregnancy

  • Pediatrics: Initial resuscitation is with 20 mL/kg boluses of balanced crystalloid. Hypotonic solutions must be avoided due to the risk of cerebral edema. Dosing for blood products and medications is weight-based.
  • Pregnancy: Physiologic changes include a 40-50% increase in plasma volume and relative anemia. The pregnant patient can lose a significant amount of blood before showing signs of hypotension. Fetal well-being must be continuously monitored as it is a sensitive indicator of maternal perfusion.

References

  1. Dhillon NK, Kwon J, Coimbra R. Fluid resuscitation in trauma: What you need to know. J Trauma Acute Care Surg. 2025;98(1):20–29.
  2. Ramesh GH, Uma JC, Farhath S. Fluid resuscitation in trauma: what are the best strategies and fluids? Int J Emerg Med. 2019;12:38.
  3. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350(22):2247–2256.
  4. Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med. 2012;367(20):1901–1911.
  5. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in severe trauma: the PROPPR trial. JAMA. 2015;313(5):471–482.
  6. Meneses E. Massive transfusion protocol in adult trauma population. Transfus Apher Sci. 2020;59:102856.
  7. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients: CRASH-2. Lancet. 2010;376(9734):23–32.
  8. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign guidelines 2021. Crit Care Med. 2021;49(11):e1063–e1143.
  9. Bulger EM, May S, Kerby JD, et al. Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock. Ann Surg. 2011;253(3):431–441.
  10. Nadim MK, Durand F, Kellum JA, et al. Management of the critically ill patient with cirrhosis. J Hepatol. 2016;64(3):717–735.
Previous Topic
Back to Lesson
Next Topic